# The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma

Source: https://onco.cc/trials/nct07565285/  
OnCo record `nct07565285` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab in melanoma, run by Primmune Therapeutics, Inc., now recruiting.

## Summary

The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma is a phase 2 interventional study registered as NCT07565285 by Primmune Therapeutics, Inc., with 48 participants planned, started 2026-07-01 and due to reach its primary completion in 2027-12. Interventions recorded: PRTX007, Pembrolizumab. Conditions listed: Melanoma Stage III. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07565285
- Phase: 2
- Setting: A Phase 2 Study to Investigate the Activity of Neoadjuvant PRTX007 Combined With Pembrolizumab in Participants With Stage III Melanoma (INFLECTION-003)
- Sponsor: Primmune Therapeutics, Inc.
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT07565285: https://clinicaltrials.gov/study/NCT07565285

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [PRTX007](https://onco.cc/drugs/prtx007/)

---
JSON: https://onco.cc/api/v1/entities/nct07565285.json